CorTechs Labs Inc. expands NeuroQuant's US Market reach with expanded distribution agreement with Invivo Corporation.

    CorTechs Labs Inc. expands NeuroQuant's US Market reach with expanded
               distribution agreement with Invivo Corporation.

PR Newswire

LA JOLLA, Calif., Feb. 4, 2014

LA JOLLA, Calif., Feb. 4, 2014 /PRNewswire/ -- CorTechs Labs is pleased to
announce the renewed and expanded partnership and distribution agreement with
Invivo Corporation (subsidiary of Philips Healthcare) for NeuroQuant^®, the
leading software solution for volumetric brain atrophy in the US healthcare
market. As the only FDA approved solution that automatically quantifies the
volumes of brain structures, NeuroQuant^® is a key part of Invivo's DynaSuite
Neuro Imaging Solution. "We're pleased to expand our relationship with
Invivo. With great expertise and presence in advanced clinical solutions for
MRI, Invivo has been a terrific partner and has demonstrated exceptional
growth with our NeuroQuant^® product in the US," said Guri Stark, CorTechs
Labs' CEO. "We look forward to partnering with Invivo to continue
NeuroQuant^®'s growth momentum and establishing our vision to have
NeuroQuant^® become the standard test for all brain disorders, including
Alzheimer's disease, epilepsy and traumatic brain injury."

"CorTechs Labs is a pioneer in the area of software for the aid of brain
diagnostics and has a tremendous track record of reliability and automation in
clinical practices." Said Tom Tynes, Director of Strategic Business
Development at Invivo. "We look forward to continuing to offer our DynaSuite
Neuro Imaging solution with NeuroQuant^®, benefitting from its innovative
approach to providing the much needed quantitative brain volumetric
information."

About CorTechs Labs
CorTechs Labs develops and markets cutting-edge brain imaging solutions used
by neurologists and radiologists in hundreds of clinics and research centers
around the world. CorTechs' flagship product, NeuroQuant^®, is a
breakthrough, 510(k) cleared medical device that makes quantitative analysis
of MRI images of the human brain a routine part of clinical practice. As the
only FDA cleared medical device capable of automatically detecting and
quantifying atrophy in the human brain, NeuroQuant^®brings sophisticated,
accurate, and fully automated MRI post-processing capabilities to the
physician's desktop or mobile device. This provides neurologists,
radiologists, and clinical researchers with a convenient and cost-effective
means to quantify atrophy of brain structures to help diagnose a variety of
brain disorders, including conditions such as Alzheimer's disease, epilepsy
and traumatic brain injury.

About Invivo Corporation
Invivo Corporation is a subsidiary of Philips Healthcare and has an over
20-year history as the pioneer of progressive MRI coils, advanced clinical
solutions, and MRI-compatible interventional devices. Invivo prides itself on
successfully developing and manufacturing high-value-added medical products to
enhance MR image quality, improve physicians' diagnostic confidence and
patients' health care experience. For more information please visit
www.invivocorp.com.

SOURCE CorTechs Labs, Inc.

Website: http://www.cortechslabs.com
Contact: Shelly Adams, CorTechs Labs, Inc., +1 858 459 9704,
press@cortechslabs.com
 
Press spacebar to pause and continue. Press esc to stop.